Diagnosis, Screening, and Early Detection of Acute Myeloid Leukemia

• Early signs of acute myeloid leukemia are often vague and non-specific, which is part of why the disease can be missed at first.
• A definitive acute myeloid leukemia diagnosis needs more than blood work: bone marrow aspiration and biopsy, plus genetic testing, confirm AML and classify its subtype.
• There is no standard screening test for AML in people without symptoms; guidance instead centers on recognizing risk factors and talking with a doctor.
• Cytogenetic analysis, molecular testing, and flow cytometry are central to classifying AML accurately and can help guide treatment decisions.
• Persistent or unusual symptoms call for prompt medical evaluation rather than self-diagnosis.

Recognizing Early Signs of AML

Because AML crowds out normal blood cell production in the bone marrow, its earliest signs usually trace back to a shortage of healthy red blood cells, platelets, or white blood cells. On their own, none of these changes points specifically to AML, which is one reason the disease is often missed early.

Common Non-Specific Symptoms

Many patients first notice fatigue, weakness, or paleness tied to anemia; easy bruising or unusual bleeding, such as nosebleeds or bleeding gums, tied to a low platelet count; or frequent, hard-to-treat infections tied to a shortage of healthy white blood cells. Unexplained weight loss, reduced appetite, and night sweats can also appear.

When to Consult a Doctor

Persistent, worsening, or unexplained versions of these symptoms are worth discussing with a doctor. None of them confirms AML by itself, but only a medical evaluation — not self-diagnosis — can tell the difference between AML and far more common causes of the same symptoms, and starting that evaluation sooner leaves more room for early treatment planning.

The Acute Myeloid Leukemia Diagnosis Process

Reaching a definitive acute myeloid leukemia diagnosis typically starts with blood tests and moves toward a bone marrow exam and specialized lab analyses that confirm the diagnosis and classify the specific AML subtype.

Initial Blood Tests

Diagnosis commonly begins with a complete blood count (CBC), which measures red blood cell and platelet levels along with how many white blood cells are present and what types they are. In AML, the CBC is often abnormal, commonly showing a high or low white blood cell count alongside low platelets and red blood cells. A peripheral blood smear, where a blood sample is examined under a microscope, can reveal blast cells — immature white blood cells that don’t normally appear in circulating blood — along with other changes in cell number and shape.

Bone Marrow Biopsy and Analysis

If blood tests point toward AML, doctors confirm it by taking marrow and a bone fragment directly from the hip or breastbone through a needle — the aspiration draws liquid marrow, while the biopsy takes a solid sample for a pathologist to examine under a microscope. According to the National Cancer Institute (NCI), AML is generally confirmed when at least 20% of the bone marrow cells are blasts, or when certain gene changes are present even at a lower blast percentage. These samples also provide material for the cytogenetic and molecular testing described below, which further refine the diagnosis and inform treatment planning.

Current Approaches to AML Screening

There is currently no standard, evidence-based screening test for leukemia, including AML, in people without symptoms — unlike some other cancers with established screening programs. Testing is instead reserved for people who have symptoms or recognized risk factors.

Risk Factors and Targeted Screening

Rather than general population screening, current guidance focuses on risk factors that can prompt closer monitoring. This includes growing older, prior cancer treatment with chemotherapy or radiation, contact with ionizing radiation or industrial chemicals like benzene, and having previously been diagnosed with a blood condition such as myelodysplastic syndrome. None of these factors guarantees that AML will occur — many people with several of them never develop the disease, while others with none of them still do — and anyone uncertain about their own risk can raise it with their doctor.

Genetic Predisposition

Certain inherited conditions further raise AML risk, including Down syndrome, Fanconi anemia, Li-Fraumeni syndrome, and neurofibromatosis type 1, among other inherited bone marrow failure or cancer-predisposition syndromes. People with one of these conditions, or a strong family history of AML, may benefit from discussing genetic counseling and closer monitoring with their doctor, though this remains a targeted approach rather than routine screening for the general public.

Advanced Diagnostic Techniques for AML

Beyond blood counts and bone marrow examination, additional lab techniques provide the detailed picture needed for an accurate acute myeloid leukemia diagnosis and subtype classification.

Cytogenetics and Molecular Testing

Cytogenetic testing looks at the chromosomes in a blood or marrow sample to spot structural abnormalities — pieces that are broken, missing, rearranged, or duplicated; fluorescence in situ hybridization (FISH) can add further sensitivity. APL is one well-known example: this AML subtype arises from a swap between chromosome 15 and chromosome 17 that fuses two genes into the abnormal PML-RARA gene, a change that tests like reverse transcription–polymerase chain reaction (RT-PCR) can pick up; recognizing APL matters because it calls for urgent treatment. Separately, molecular testing looks for specific gene or chromosome changes in blood or bone marrow cells that can factor into subtype and prognosis and can also guide treatment — for example, whether AML carries a mutation in the FLT3 gene affects certain treatment choices.

Flow Cytometry

Flow cytometry stains cells from a blood, bone marrow, or tissue sample with a fluorescent dye and measures how they react as they pass through a beam of light, revealing details such as cell size, shape, and surface markers. In AML, this technique — along with related tests such as immunophenotyping — helps confirm the leukemia cells’ lineage, distinguish AML from other types of leukemia, and identify AML subtypes based on their marker patterns.

Frequently Asked Questions

Who should consider screening for acute myeloid leukemia?

There is no standard screening test for AML in people without symptoms. People with recognized risk factors — such as past chemotherapy or radiation treatment, long-term benzene exposure, a personal history of myelodysplastic syndrome, or certain inherited syndromes — can talk with their doctor about how closely to monitor for early changes.

What are the most critical early signs of acute myeloid leukemia?

Persistent fatigue, unusual bruising or bleeding, and frequent infections are among the most notable early signs of AML, along with less specific changes like weight loss or night sweats. Because these symptoms overlap with common, non-cancerous conditions, it’s their persistence or combination — not any single sign — that warrants prompt medical evaluation.

Beyond initial blood tests, how is AML diagnosed definitively?

A definitive AML diagnosis requires a bone marrow aspiration and biopsy, generally confirmed — per NCI — by finding that at least 20% of bone marrow cells are blasts, or by identifying certain gene changes even at a lower blast percentage. Cytogenetic analysis, molecular testing, and flow cytometry are then used to classify the specific AML subtype and help guide treatment planning.

Sources

• National Cancer Institute – Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version
• National Cancer Institute – Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies Treatment (PDQ®)–Patient Version
• National Cancer Institute – Leukemia—Patient Version
• MedlinePlus – Acute Myeloid Leukemia – Adult